首页> 外文OA文献 >Mucoadhesive Microspheres for Gastroretentive Delivery of Acyclovir: In Vitro and In Vivo Evaluation
【2h】

Mucoadhesive Microspheres for Gastroretentive Delivery of Acyclovir: In Vitro and In Vivo Evaluation

机译:粘膜粘附微球用于阿昔洛韦的胃滞留递送:体外和体内评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present investigation was to evaluate the potential use of mucoadhesive microspheres for gastroretentive delivery of acyclovir. Chitosan, thiolated chitosan, Carbopol 71G and Methocel K15M were used as mucoadhesive polymers. Microsphere formulations were prepared using emulsion-chemical crosslinking technique and evaluated in vitro, ex-vivo and in-vivo. Gelatin capsules containing drug powder showed complete dissolution (90.5 ± 3.6%) in 1 h. The release of drug was prolonged to 12 h (78.8 ± 3.9) when incorporated into mucoadhesive microspheres. The poor bioavailability of acyclovir is attributed to short retention of its dosage form at the absorption sites (in upper gastrointestinal tract to duodenum and jejunum). The results of mucoadhesion study showed better retention of thiolated chitosan microspheres (8.0 ± 0.8 h) in duodenal and jejunum regions of intestine. The results of qualitative and quantitative GI distribution study also showed significant higher retention of mucoadhesive microspheres in upper GI tract. Pharmacokinetic study revealed that administration of mucoadhesive microspheres could maintain measurable plasma concentration of acyclovir through 24 h, as compared to 5 h after its administration in solution form. Thiolated chitosan microsphere showed superiority over the other formulations as observed with nearly 4.0-fold higher AUC0–24 value (1,090 ± 51 ng h/ml) in comparison to drug solution (281 ± 28 ng h/ml). Overall, the result indicated prolonged delivery with significant improvement in oral bioavailability of acyclovir from mucoadhesive microspheres due to enhanced retention in the upper GI tract.
机译:本研究的目的是评估粘膜粘附微球在阿昔洛韦的胃滞留递送中的潜在用途。壳聚糖,硫醇化壳聚糖,Carbopol 71G和Methocel K15M被用作粘膜粘附聚合物。使用乳液-化学交联技术制备微球制剂,并在体外,离体和体内进行评估。含有药粉的明胶胶囊在1小时内显示完全溶解(90.5%±3.6%)。当掺入粘膜粘附微球时,药物的释放被延长至12小时(78.8±±3.9)。阿昔洛韦的生物利用度差归因于其剂型在吸收位点(在上消化道至十二指肠和空肠)的滞留时间短。粘膜粘附研究的结果表明,在十二指肠和空肠区域中,巯基化壳聚糖微球的保留时间(8.0±±0.8小时)更好。定性和定量胃肠道分布研究的结果还表明,粘膜粘附性微球在较高的胃肠道中的保留率更高。药代动力学研究表明,粘膜粘附微球给药可在24小时内维持可测量的阿昔洛韦血浆浓度,而溶液形式给药后仅5 h。与药物溶液(281san±28 ng h / ml)相比,硫代壳聚糖微球显示出优于其他配方的优势,AUC0-24值(1,090±51 ng h / ml)高出近4.0倍。总体而言,该结果表明,由于增强了在上消化道的滞留性,阿昔洛韦从粘膜粘附性微球的口服递送延长,口服生物利用度显着提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号